Sara Bastian
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemother Pharmacol 2024; 94:349-360.
15.06.2024Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
15.06.2024Cancer Chemother Pharmacol 2024; 94:349-360
Mc Laughlin Anna M, Hess Dagmar, Michelet Robin, Colombo Ilaria, Haefliger Simon, Bastian Sara, Rabaglio-Poretti Manuela, Schwitter Michael, Fischer Stefanie, Eckhardt Katrin, Hayoz Stefanie, Kopp Christoph, Klose Marian, Sessa Cristiana, Stathis Anastasios, Halbherr Stefan, Huisinga Wilhelm, Jörger Markus, Kloft Charlotte
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribi K, Maranta A, Bastian S, von Moos R, Jörger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. Eur J Cancer 2024; 200:113600.
05.02.2024First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
05.02.2024Eur J Cancer 2024; 200:113600
Mark Michael, Froesch Patrizia, Gysel Katrin, Rothschild Sacha I, Addeo Alfredo, Ackermann Christoph Jakob, Chiquet Sabrina, Schneider Martina, Ribi Karin, Maranta Angela Fischer, Bastian Sara, von Moos Roger, Jörger Markus, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Eur J Cancer 2024; 201:113588.
02.02.2024TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
02.02.2024Eur J Cancer 2024; 201:113588
Colombo Ilaria, Koster Kira-Lee, Holer Lisa, Haefliger Simon, Rabaglio-Poretti Manuela, Bastian Sara, Schwitter Michael, Eckhardt Katrin, Hayoz Stefanie, Mc Laughlin Anna M, Kloft Charlotte, Klose Marian, Halbherr Stefan, Baumgartner Christian, Sessa Cristiana, Stathis Anastasios, Hess Dagmar, Jörger Markus
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
23.07.2022Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
23.07.2022Br J Clin Pharmacol 2022; 88:5336-5347
Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich
Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma
Jörger M, Gueller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol 2019; 10:373-378.
01.04.2019Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma
01.04.2019J Gastrointest Oncol 2019; 10:373-378
Jörger Markus, Gueller Ulrich, Bastian Sara, Driessen Christoph, von Moos Roger
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol 2018; 10:304-310.
14.12.2018Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
14.12.2018J Geriatr Oncol 2018; 10:304-310
Kienle Dirk L, Andrieu Christiane, Bernhard Juerg, Lugli Alessandro, Baertschi Daniela, Helbling Daniel, Saletti Piercarlo, Kueng Marc, Bastian Sara, Horber Daniel, Koeberle Dieter, Winterhalder Ralph C, Quagliata Luca, Wicki Andreas, Ribi Karin, Dietrich Daniel, von Moos Roger
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome
Fischer A, Bastian S, Cogliatti S, Mey U, Saub J, Schanz U, Padberg S, Hohloch K. Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome. Hematol Oncol 2017
06.07.2017Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome
06.07.2017Hematol Oncol 2017
Fischer Angela, Bastian Sara, Cogliatti Sergio B., Mey Ulrich, Saub Jenny, Schanz Urs, Padberg Sgier, Hohloch Karin
Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature
Bastian S, Clerici T, Neuweiler J, Cerny T, Früh M. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. Onkologie 2011; 34:665-70.
21.11.2011Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature
21.11.2011Onkologie 2011; 34:665-70
Bastian Sara, Clerici Thomas, Neuweiler Jörg, Cerny Thomas, Früh Martin